Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.61 |
| ▸ | FSHR | P23945 | 16/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2194212 | 1.00 | TSHR (0.61) | TSHRFSHRLMNATP53MMP1 | |
| SCHEMBL2192031 | 0.89 | TSHR (0.59) | TSHRFSHRLMNATP53KDM4E | |
| SCHEMBL3655121 | 0.85 | FSHR (0.62) | TSHRFSHRTP53NPC1RAB9A | |
| SCHEMBL2194165 | 0.84 | TSHR (0.65) | TSHRFSHR | |
| SCHEMBL2192026 | 0.83 | TSHR (0.68) | TSHRFSHR | |
| SCHEMBL2192676 | 0.80 | TSHR (0.64) | TSHRFSHR | |
| SCHEMBL2194582 | 0.79 | FSHR (0.61) | TSHRFSHRNPC1RAB9A | |
| SCHEMBL2194358 | 0.78 | TSHR (0.62) | TSHRFSHR | |
| SCHEMBL2191415 | 0.78 | TSHR (0.55) | TSHRFSHRLMNA | |
| SCHEMBL2191417 | 0.78 | TSHR (0.55) | TSHRFSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172267-A1 | TSH receptor antagonizing tetrahydroquinoline compounds | N.V. ORGANON | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172267-A1 | TSH receptor antagonizing tetrahydroquinoline compounds | TSHR, MC1R, TRHR | TSHR 1/4885FSHR 21/4885LMNA 1653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.